NBC Securities Inc. Increases Stock Holdings in Masimo Co. (NASDAQ:MASI)

NBC Securities Inc. increased its holdings in Masimo Co. (NASDAQ:MASI) by 47.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 228 shares of the medical equipment provider’s stock after buying an additional 73 shares during the period. NBC Securities Inc.’s holdings in Masimo were worth $30,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Fifth Third Bancorp lifted its holdings in shares of Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 98 shares in the last quarter. Oak Thistle LLC lifted its stake in Masimo by 5.2% in the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock valued at $262,000 after buying an additional 103 shares in the last quarter. GAMMA Investing LLC grew its holdings in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 111 shares during the last quarter. HHM Wealth Advisors LLC increased its position in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares in the last quarter. Finally, M&G Plc raised its holdings in shares of Masimo by 4.8% in the second quarter. M&G Plc now owns 3,240 shares of the medical equipment provider’s stock worth $408,000 after acquiring an additional 149 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on MASI shares. BTIG Research lifted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a report on Friday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Friday, September 20th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.33.

Masimo Stock Up 1.2 %

Shares of NASDAQ:MASI opened at $144.66 on Monday. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. The firm has a market cap of $7.69 billion, a price-to-earnings ratio of 98.41 and a beta of 0.99. The stock’s 50-day moving average price is $125.67 and its two-hundred day moving average price is $125.03. Masimo Co. has a 12-month low of $75.36 and a 12-month high of $153.93.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. During the same period last year, the company earned $0.62 earnings per share. The company’s quarterly revenue was up 9.0% on a year-over-year basis. On average, research analysts forecast that Masimo Co. will post 3.88 EPS for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.